Humacyte, Inc.

About Humacyte, Inc.

Humacyte Global, Inc. is pioneering a bioengineering platform to develop and manufacture universally implantable, regenerative human tissues and organs. Their mission is to treat a wide variety of diseases, injuries, and chronic conditions by providing off-the-shelf biologic tissues that are accessible to a broader patient population.

Products & Services

Symvess™:An acellular tissue engineered vessel approved by the U.S. FDA for the treatment of extremity vascular trauma.

Acellular Tissue Engineered Vessel (ATEV™):Met primary endpoints in a Phase 3 clinical trial for arteriovenous access in hemodialysis.

Advanced Tissue Constructs:Investigational products for applications such as tracheal replacement, esophageal replacement, and urinary conduit.

Symvess® (acellular tissue engineered vessel)

Acellular Tissue Engineered Vessel (ATEV™)

Specialties

Bioengineering of human tissues and organs Acellular tissue engineered vessels Regenerative medicine Treatment of vascular trauma Arteriovenous access for hemodialysis universally implantable regenerative human tissues bioengineered tissues and organs vascular trauma treatment hemodialysis access

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2026-06-10 FD: 2026-06-10	3 investors
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 20000000 MR: - FA: 20 million FAN: 20000000	D: 2026-03-19 FD: 2026-03-19	2 investors
3	RT: Debt T: - FT: Debt	A: 77500000 MR: - FA: up to $77.5 million FAN: 77500000	D: 2025-12-16 FD: 2025-12-16	1 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 60000000 MR: - FA: 60.0 million FAN: 60000000	D: 2025-10-07 FD: 2025-10-07	1 investors
5	RT: Public Offering T: - FT: Public Offering	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2025-03-25 FD: 2025-03-25	-
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 15000000 MR: - FA: 15.0 million FAN: 15000000	D: 2024-11-14 FD: 2024-11-14	1 investors
7	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 30000000 MR: - FA: $30.0 million FAN: 30000000	D: 2024-10-04 FD: 2024-10-04	1 investors
8	RT: Revenue-based funding T: - FT: Revenue-based funding	A: 160000000 MR: - FA: up to $160 million FAN: 160000000	D: 2023-05-12 FD: 2023-05-12	1 investors

Public Offering Latest

2026-06-10

$50.0M

3 investors (Pro only)

Registered Direct Offering 2026-03-19

$20.0M

Debt 2025-12-16

$77.5M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Laura Niklason

Co-Founder and CEO

L

Laura E. Niklason

Founder, President, Chief Executive Officer

D

Dale Sander

Chief Corporate Development Officer, Chief Financial Officer & Treasurer

S

Shamik Parikh

Chief Medical Officer

S

Sabrina Osborne

Chief People Officer

L

Lisa Molyneux

Executive Vice President, Enterprise Planning & Analysis

View 10 more team members with Pro

Unlock Full Team Directory

Recent News

Humacyte, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised